Seagen
Subsidiary of Pfizer (PFE) · United States
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Anti-CD30 antibody-drug conjugateAntibody–drug conjugate | Non-Small Cell Lung CancerDiffuse Large B-Cell LymphomaNon-Hodgkin LymphomaCutaneous T-Cell Lymphoma Large B-Cell Lymphoma, Peripheral T-Cell Lymphoma, High-Grade B-Cell Lymphoma | |
Tisotumab Vedotin Humax-tf-adc(Tivdak) | Approved | Tissue Factor (TF)Antibody–drug conjugate | Non-Small Cell Lung CancerCervical Cancer |
| Phase 3 | PD-L1Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 3 | Integrin beta-6 (ITGB6)Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | CEACAM5Antibody–drug conjugate | Non-Small Cell Lung CancerColorectal Cancer |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
March 2028 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.